Re:The Price of Remission
by comrade1234 on Saturday May 10, 2025 @07:49PM
(#43950006)
It leaves them vulnerable to takeover, for one. They have over $1B cash right now to pay for clinical trials in other markets as well as new indications but their valuation is about 5x that. Someone could leverage the $1B as part of a hostile takeover.
[ Parent
| on HN ]
There are no comments on this comment yet.